Fenfluramine: Riddle or Rosetta stone?

European Respiratory Journal

Volumn 31, Issue 2, 2008, Pages 232-235

  Weir, E K ^a,b   Obreztchikova, M ^a   Hong, Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FENFLURAMINE; POTASSIUM CHANNEL; SEROTONIN; ANOREXIGENIC AGENT; SEROTONIN UPTAKE INHIBITOR;

DISEASE COURSE; DRUG ACTIVITY; EDITORIAL; FIBROSIS; FOLLOW UP; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SEROTONIN BLOOD LEVEL; VALVULAR HEART DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; INCIDENCE; METABOLISM; NOTE; PATHOPHYSIOLOGY; PULMONARY VALVE; RAT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANIMALS; APPETITE DEPRESSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FENFLURAMINE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; PULMONARY VALVE; RATS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 40649123583     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00160407     Document Type: Editorial

References (39)

1. Gurtner H. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter. Bull Eur Physiopath Res 1979; 15: 897-923.
2. Greiser E. Epidemiologische untersuchungen zum zusammenhang zwischen appetitzueglere innahme und primaer vasculaer pulmonaler hypertonie. [Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension.] Internist 1973; 14: 437-442.
3. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
4. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
5. Thompson J, Machado R, Pauciulo M, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J Med Genet 2003; 37: 741-745.
6. From the Centers for Disease Control and Prevention. Cardiac valuvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. JAMA 1997; 278: 1729-1731.
7. Gustafsson B, Tømmerås K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111: 1517-1522.
8. Fitzgerald L, Burn T, Brown B, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000; 57: 75-81.
9. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006; 113: 81-89.
10. Celada P, Martín F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994; 55: 1237-1243.
11. Eddahibi S, Raffestin B, Launay J, Sitbon M, Adnot S. Effect of dexfenfluarmine treatment in rats exposed to acute and chronic hypoxia. Am J Respir Crit Care Med 1998; 157: 1111-1119.
12. Zolkowska D, Rothman R, Baumann M. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 2006; 318: 604-610.
13. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819.
14. Kawut S, Horn E, Berekashvili K, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006; 19: 370-374.
15. Johnson G, Leis L, Dunlop P, Weir E. The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost 2003; 1: 2663-2668.
16. Herve P, Launay J, Scrobohaci M, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
17. Morecroft I, Dempsie Y, Bader M, et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007; 49: 232-236.
18. Izikki M, Hanoun N, Marcos E, et al. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol 2007; 293: L1045-L1052.
19. Eddahibi S, Fabre V, Boni C, et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res 1999; 84: 329-336.
20. Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000; 105: 1555-1562.
21. MacLean M, Deuchar G, Hicks M, et al. Over-expression of the 5-hydroxytryptamine transporter gene: effect on pulmonary haemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004; 109: 2150-2155.
22. Lee S, Weng W, Lanzillo J, Fanburg B. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266: L46-L52.
23. Rothman R, Ayestas M, Dersch C, Baumann M. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999; 100: 869-875.
24. Lee S, Wang W, Fanburg B. Dexfenfluramine as a mitogen signals through the formation of superoxide anion. FASEB J 2001; 15: 1324-1325.
25. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
26. Eddahibi S, Guignaber C, Barlier-Mur A, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006; 113: 1857-1864.
27. Marcos E, Fadel E, Sanchez O, et al. Serotonin transporter and receptors in various forms of human pulmonary hypertension. Chest 2005; 128: Suppl. 6, 552S-553S.
28. Launay J, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002; 8: 1129-1135.
29. Liu Y, Suzuki Y, Day R, Fanburg B. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004; 95: 579-586.
30. Weir E, Reeve H, Huang J, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220.
31. Hong Z, Olschewski A, Reeve H, Nelson D, Hong F, Weir E. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol 2003; 286: L531-L538.
32. Reeve H, Michelakis E, Nelson D, Weir E, Archer S. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol 2001; 90: 2249-2256.
33. Bonnet S, Michelakis E, Porter C, et al. An abnormal mitochondrial -HIF1a - Kv channel pathway disrupts oxygen-sensing and triggers pulmonary arterial hypertension (PAH) in fawn-hooded rats: similarities to human PAH. Circulation 2006; 113: 2630-2641.
34. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406.
35. + channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C970-C979.
36. Rezaie-Majd S, Murar J, Nelson D, et al. Increased release of serotonin from rat ileum due to dexfenfluramine. Am J Physiol 2004; 287: R1209-R1213.
37. Guignabert C, Izikki M, Tu L, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006; 98: 1323-1330.
38. Cogolludo A, Moreno L, Lodi F, et al. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1 and Kv1.5 channel internalization. Circ Res 2006; 98: 931-938.
39. Fantozzi I, Platoshyn O, Wong A, et al. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am J Physiol 2006; 291: L993-L1004.